By Tilly Boateng
In January 2026, the World Economic Forum published a landmark report titled Women’s Health Investment Outlook: 6% of Funding for Nearly 50% of the Population that exposes one of the most significant and persistent inequities in global health. The report reveals that women’s health receives just six percent of private healthcare investment worldwide, even though women and girls make up almost half of the global population.
This stark imbalance reflects deep structural gaps in healthcare research, innovation, and capital allocation, and it highlights an urgent need for a new approach to investing in health systems, technological innovation, and therapeutic solutions tailored to women. This article unpacks the key findings, explains why the funding gap matters, and explores the economic and social opportunities that arise if these disparities are addressed.
The Funding Landscape
The most striking statistic from the WEF report is that only six percent of private healthcare investment goes into women’s health-related initiatives, despite women representing nearly 50 percent of the global population. That means that for every dollar invested privately in healthcare, less than seven cents go toward improving women’s health outcomes and developing solutions tailored specifically to women’s needs.
Even more revealing is how this limited funding is distributed within women’s health. According to the report, about 90 percent of the investment that does exist is concentrated in just a few areas: women’s cancers, reproductive health, and maternal health. These areas are important, but they represent only a fraction of the full spectrum of health conditions that affect women.
This leaves many conditions that are either unique to women, more prevalent in women, or experienced differently by women underfunded or ignored entirely. Examples include cardiovascular disease, osteoporosis, menopause, Alzheimer’s disease, endometriosis, polycystic ovary syndrome (PCOS) and menstrual health. Collectively these areas account for a small fraction of the investment pie but represent significant unmet health needs.
Why the Gap Exists
According to the report and its authors, the underinvestment stems from multiple factors, including historical bias in medical research and development, a lack of comprehensive data on women’s health outcomes, and narrow definitions of what constitutes “women’s health”. For decades, clinical standards, research trial designs, and innovation pathways were built around male physiology, with the assumption that results would automatically translate to women. This assumption has repeatedly proven false, leading to poorer diagnostic outcomes, treatment effectiveness discrepancies, and overall knowledge gaps about women’s health.
Another reason is that many conditions affecting women outside of reproductive health have been treated as secondary or lower priority by investors and healthcare leaders. While maternal care and cancer research receive significant attention and some public support, conditions like menopause, cardiovascular disease, and chronic neurological disorders have not attracted the same level of private capital or strategic focus.
Beyond Reproductive Health
One of the report’s core insights is that women’s health cannot be defined only by reproductive milestones. Women experience health differently across the lifespan, with conditions that go far beyond reproduction. Cardiovascular disease, for example, is the leading cause of death in women globally, yet private investment in women’s cardiovascular health is a tiny fraction of total funding. In some analyses cited in the broader research ecosystem, women’s specific cardiovascular investment represents less than 0.01 percent of overall cardiovascular research funding.
Menopause is another example. It affects every woman who reaches midlife, yet research and treatments for menopause-related symptoms and long-term health effects remain underfunded compared to how widespread the condition is. Osteoporosis affects women at far higher rates than men, especially after menopause, but investment in prevention and treatment also lags behind other health priorities. Likewise, Alzheimer’s disease disproportionately affects women, yet current investment levels do not match this burden.
The report also highlights that conditions like endometriosis and PCOS, which collectively affect tens of millions of women worldwide, receive well under two percent of women’s health investment. This mismatch between disease prevalence and capital allocation underscores the systemic blind spots in healthcare financing and innovation.
Economic Opportunity
Beyond the moral and social imperatives of investing in women’s health, the report underscores a significant economic opportunity. According to analysis by the Boston Consulting Group included in the Outlook, addressing four key underserved areas in the United States, cardiovascular disease, osteoporosis, menopause, and Alzheimer’s, could unlock a market opportunity exceeding 100 billion US dollars by 2030. This estimate is based on expanded access to standard care for women in these categories.
Economic gains extend beyond direct market value. Healthy women contribute more effectively to the workforce, increase productivity, reduce the economic strain on health systems, and support better health outcomes for children and families. The health of women is deeply linked to societal resilience, educational outcomes, and long-term economic growth. Investing in women’s health is not just a moral call but a strategic economic imperative.
Investment Trends and New Tools
To paint a clearer picture of where capital is flowing and where it is not, the WEF report introduces the Women’s Health Investment Index. This index aggregates data from thousands of private sector transactions between 2020 and 2025, allowing investors, policymakers, and healthcare developers to visualize financing patterns and identify unmet needs. It is a first step toward making women’s health an investible and measurable category at scale.
This index works much like climate finance tracking helped grow investment in climate solutions. By showing where capital is going, where it is scarce, and where the greatest opportunities exist, the index aims to reduce uncertainty for investors and inspire more strategic allocation of resources. Clear data and transparency are essential for building markets around underfunded health needs.
What Needs to Change
The report highlights several key priorities to help close the investment gap:
- Expand the evidence base: More clinical and economic data tailored specifically to women’s health is essential for attracting investment and building effective products and services.
- Promote transparency: Investors need clear, consistent data to evaluate opportunities and risks in women’s health markets.
- Broaden focus areas: Capital should be directed toward high-burden conditions that affect women uniquely or disproportionately.
- Leverage blended finance: Combining public, private, and philanthropic capital can help de-risk early-stage investment and demonstrate proof points for scaling solutions.
- Encourage innovation: Policies and regulatory frameworks that support women’s health innovation can help spur research and commercial development.
In The End
The Women’s Health Investment Outlook 2026 exposes a stark but solvable health inequity: women’s health is chronically underfunded relative to its importance to global wellbeing and economic growth. Only six percent of private healthcare investment flows into this critical domain, and nearly 90 percent of that is concentrated in a narrow set of categories. This imbalance leaves many conditions that affect women most acutely overlooked and under-resourced.
The report is a wake-up call for investors, policymakers, healthcare leaders, and innovators. By expanding investment beyond traditional women’s health areas and building data transparency, the global community can unlock not only better health outcomes for women but also economic value that benefits society as a whole. Achieving equity in women’s health funding is not only the right thing to do. It is an opportunity that the world can no longer afford to ignore.
